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Leslie Tucker, Consultant
overview — Researchers are exploring how genetic variations among 
individuals may help explain why a drug can work well in some people and 
poorly (or not at all) in others, including those who appear to have the same 
disease. Pharmacogenomics, as this new field is called, aims to help physicians 
make use of genetic tests to distinguish among patients whose genetic char-
acteristics predispose them to respond in certain ways to certain medicines. 
If physicians can use this information to quickly and reliably choose the ap-
propriate drug at the most effective dose for each patient, they may produce 
better patient outcomes and save health care dollars. An understanding of the 
genetic variables that influence drug response could also help pharmaceutical 
companies design new, more effective therapies. Although it is early in the 
development of pharmacogenomics, there are indications that this promising 
new technology has begun to challenge public policies to keep pace. Issues 
surrounding the safety, access, cost, and ethical dimensions of new clinical 
genetic tests and targeted drug therapies will need to be addressed if pharma-
cogenomics is to fulfill its potential. Conceptually, few of the issues raised by 
pharmacogenomics are unique to the field—or even to genetics—but all will 
have to be considered explicitly in the context of this new technology.
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Pharmacogenomics:  
A Primer for Policymakers
Americans and their health insurers—both private and public—spend more 
than $250 billion per year on pharmaceuticals, and for most of the past 15 
years that spending has been the fastest growing component of health care 
costs.1 According to some estimates, it can cost nearly $1 billion to bring 
one drug to market.2 A large share of that amount underwrites clinical tri-
als that drug manufacturers carry out in order to prove a drug’s safety and 
effectiveness. Yet many currently approved drugs are effective in less than 
50 percent of the people treated with them,3 and adverse drug reactions are 
the sixth leading cause of hospitalization and death in the United States. 
Building on the tools and knowledge generated by the Human Genome 
Project, pharmacogenomics is a rapidly growing field that explores the 
contribution of genetics to drug safety and efficacy—specifically, how ge-
netic variations affect individuals’ responses to drugs. Genes determine the 
make-up of human proteins, including enzymes, receptors, transporters, and 
other molecules involved in drug and disease pathways (see illustration, next 
page). Pharmacogenomics uses genetic tests to classify patients and diseases 
according to variants in these genes. This information can help predict who 
will or will not benefit from a particular drug, at what dose, and which pa-
tients may be at risk for adverse reactions. Eventually, pharmacogenomics 
may be used to design new drugs and to identify candidates for preventive 
drug regimens long before disease symptoms are apparent. 
Although headlines have proclaimed a coming genetic “revolution” in health 
care, most of the anticipated advances in pharmacogenomics are still in the 
early research stage. Massive, multi-institutional studies are just beginning to 
unravel the genetic basis of today’s most important diseases, and to identify 
the environmental, behavioral, and dietary factors that interact with gene 
variation to affect drug response. So far only a handful of drugs “tailored” 
to specific genotypes have been developed and approved. 
Bringing pharmacogenomics from the realm of basic exploratory genetics 
research to safe, effective applications in the doctor’s office will require 
enormous investment, collaboration, and innovation across the biomedical 
enterprise. Like all new medical technologies, pharmacogenomics will have 
to prove that its tools and discoveries produce real added value in treatment 
decisions and outcomes before it is widely embraced. It will also require 
new regulatory standards, safeguards, and educational initiatives to guide 
its path from bench to bedside. Finally, it will cost will money. This paper 
describes the opportunities and challenges embodied in this new technology, 
current federal efforts to advance the field, and outstanding policy issues 
related to safety, quality, access, cost, and ethical implications. 
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Genes are segments of Dna. DNA is composed of different combinations 
of four nucleic acids, or “bases,” abbreviated a,t,c and G, arranged in 
long chains in a double helix. 
the genetic sequence encodes instructions for making proteins, which 
do most of the work in living cells. Proteins include enzymes (which build 
or break down substances), receptors (which serve as signal receivers for 
a cell), transporters (which move molecules across cell membranes 
and around the body), and many other important molecules. 
Genetic instructions for making proteins are “read” or 
translated through a process called transcription.
the nucleic acid sequence of specific genes can vary from 
person to person, even within immediate family. This 
natural variation means that at least some of the proteins 
made by each person will be different from others.
Pharmacogenomics Basics: Genes, Proteins, and Drugs
Pharmacogenomic technologies try to detect genetic variations in a patient, or among patient 
populations, to help doctors select the drug compounds and doses that are most likely to work.
Drugs are designed to interact with substances in the body, 
most often proteins. Sometimes, genetic differences can 
affect how well a particular drug serves its intended func-
tion by influencing how that drug is activated, broken down, 
transported, or eliminated by the body, as well as the fit 
between the drug and its protein target.
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current aPPlicationS
Some genes control pharmacodynamics: how the drug affects the body. Oth-
ers control pharmacokinetics: how the body absorbs and disposes of a drug 
(that is, how the drug is metabolized). Pharmacogenomic techniques work 
with both processes. Examples include: 
Subtyping common diseases to help physicians choose the right drug 
therapy — What appears to be one disease in a clinical setting can turn 
out to be several different diseases at the molecular level, each requiring 
a different therapy. Cancers, for example, are a particularly promising 
area for pharmacogenomics because genetic “glitches” direct tumors 
to grow and spread in different ways and their response to treatment 
often depends on these unique characteristics.4 The classic example of a 
pharmacogenomic drug, Herceptin, is a highly effective therapy in the 
15 to 25 percent of breast cancers that have a particular genetic variant 
that causes marked overexpression of the HER2 protein (a cell growth 
promoter) and is useless against breast tumors without that variant.5 
This variety in the genetic underpinning of disease is true for many 
other diseases as well. For example, heart attacks are associated with at 
least 20 different genetic variations (many of which also have roles in 
inflammation or immunity),6 suggesting that there are multiple types 
of heart disease that are potentially treatable in different ways.
Subtyping patients to help guide drug dosing regimens (see illustration 
below) — Drugs are broken down (metabolized) in the body by enzymes. 
One family of enzymes called cytochrome P (CYP) 450 is responsible for 


Source: Adapted from Felix W. Frueh, U.S. Food and Drug Administration, “Personalized Medicine, What Is It? How Will It Affect Healthcare?” 
slides from the 11th Annual FDA Science Forum, April 26, 2005; available at www.fda.gov/Cder/genomics/scienceForum2005.pdf.
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Background Paper
January 28, 2008
national health Policy forum  |  www.nhpf.org 
breaking down more than 30 different classes of drugs, including anti-
depressants, antipsychotics, beta blockers, and some chemotherapeutic 
agents. Individual variations in the genes that produce these enzymes 
can cause different people to metabolize the same drug differently: less 
active or inactive forms of CYP enzymes that are unable to break down 
and efficiently eliminate a drug from the body (“slow metabolizers”) 
can cause the drug to build up and lead to severe overdose in patients, 
whereas very active forms (“ultrarapid metabolizers”) can cause the body 
to clear itself of a drug before it has had a chance to work. Identifying 
which variant(s) a patient has could help physicians determine the ap-
propriate dose of some medications to achieve therapeutic effects more 
quickly and avoid potential drug reactions. For example, every year in 
the United States, 2 million surgical and cardiac patients take the blood 
thinner warfarin (Coumadin®) to prevent blood clotting, but finding the 
correct dose for each person is notoriously difficult and mistakes can be 
deadly. Researchers found that differences in a gene called VKORC1, 
in tandem with specific CYP enzymes, influence how much warfarin 
is optimal for each person, a discovery that led the U.S. Food and Drug 
Administration (FDA) for the first time to recommend genetic testing on 
the label of a popular drug. A few clinically important variations in other 
metabolic enzymes also have been identified. For example, one version of 
the enzyme thiopurine methyltransferase (TPMT) prevents patients from 
metabolizing the anticancer drug 6-mercaptopurine (6MP), used to treat 
one form of childhood leukemia. Patients who have a specific mutation 
in the gene that codes for the enzyme may need less than one-tenth of 
the regular dose, and they can die if they receive a full dose.
identifying individuals who could benefit from prophylactic drug 
therapy — Many advocates are hopeful that pharmacogenomics will 
enable tailored pharmaceutical interventions to prevent disease. For 
example, a risk assessment that takes into account a patient’s genetic 
susceptibility to coronary artery disease could result in a lower thresh-
old for prescribing anticholesterol medication than is recommended 
for the population at large.7 Pharmacogenomics can also support tar-
geted primary chemoprevention, for example, by identifying women 
with BRCA1 and BRCA2 gene mutations who may benefit from using 
the drug tamoxifen to prevent breast cancer. The value of pharma-
cogenomics for disease prevention is currently limited by the fact 
that gene variants discovered so far explain only a small proportion 
of overall risk; however, ongoing discovery and characterization of 
disease “susceptibility” genes may improve risk prediction.8
In addition to its clinical applications, pharmacogenomics has some po-
tential to help drug companies and the FDA bring drugs to market more 
quickly. When drugs fail clinical trials, it is often because they cannot show 
a statistically significant therapeutic effect in a diverse population; other 
drugs fail because of safety issues in a small number of trial participants. 
Pharmacogenomics could potentially reduce the risk of these expensive fail-
ures by enabling companies to identify and recruit clinical trial participants 

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who are likely to respond favorably to the drug and to eliminate subsets 
of patients whose genotypes make them likely to suffer adverse reactions, 
thus reducing the time and number of subjects necessary to prove safety and 
efficacy. For drugs that have failed trials or been recalled from the market 
cyP enzymes and Psychotropic Drugs 
Psychiatric drugs have long been a priority for 
pharmacogenomics research because of the eco-
nomic and social burden of mental illness and 
because it is very difficult for physicians to predict 
who will respond best to which of the many avail-
able drugs. Selective serotonin reuptake inhibitors 
(SSRIs) have become the first-line drugs in the 
treatment of depression, but physicians must 
choose among more than two-dozen branded 
products in this drug class with little definitive 
clinical evidence to determine which is most likely 
to work for which patient. In addition, finding 
the correct dose usually involves a process of trial 
and error, which can lengthen the time until treat-
ment begins to help a patient. One-third of people 
treated with antidepressants do not respond to any 
medication or suffer such intolerable side effects 
that they cannot continue with the drugs.* 
Researchers know that SSRIs are metabolized by 
the CYP 450 family of enzymes, and genetic tests 
recently have become commercially available that 
can identify whether an individual has the “slow,” 
“rapid,” or “ultrarapid” metabolizer version of the 
genes that code for these enzymes. Researchers 
are now trying to uncover the specific associations 
between genetic variants in the CYP system and 
the effectiveness and side effects of specific SSRIs 
along with other antidepressants. To succeed, 
researchers will have to isolate the effects of CYP 
450 differences from the effects of other known 
and suspected genetic variants that could influence 
response to SSRIs, as well as differences in diet, 
exercise, the presence of other health conditions, 
other drugs the patient may be taking, and so on. 
The task is so complicated that government agen-
cies in both the United States and Europe have 
established research networks to divide the work 
and share data.†
Even if the specific effects of CYP 450 status become 
known, it is unclear how much or how soon such 
information will be available to assist physician de-
cisions about selecting specific SSRIs and their doses 
for individual patients. Physicians will look for 
evidence that prescribing based on CYP status im-
proves patient outcomes—evidence that, according 
to a recent AHRQ report, does not yet exist.‡ Many 
will also look to professional practice guidelines to 
inform genetic testing criteria and to help translate 
genetic test lab results into useful prescribing in-
formation; however such guidelines will require 
even more detailed levels of evidence that will take 
more time and resources to develop.§ Ultimately, a 
physician may decide that the combined influence 
of other variables in depressed or anxious patients 
may outweigh the predictive value (and expense) 
of a genetic test to look only at CYP status.
* Arline Kaplan, “Advances in Pharmacogenomics Reduce Side Effects and Save Lives,” Psychiatric Times, XXII, no. 7 (June 1, 2005); and J. Kirch-
heiner et al., “Pharmacogenetics of antidepressants and the antipsychotics: the contribution of allelic variations to the phenotype of drug response,” 
Molecular Psychiatry, 9, no. 5 (May 2004): pp. 442–473.
† These include centers within the Pharmacogenetics Research Network (PGRN), supported by the U.S. National Institutes of Health (NIH) and the 
Genes and Depression study (GENDEP), supported by the European Union and involving scientists and clinicians from ten countries.
‡ D. B. Matchar et al., Testing for Cytochrome P450 Polymorphisms in Adults With Non-Psychotic Depression Treated With Selective Serotonin 
Reuptake Inhibitors (SSRIs), Evidence Report/Technology Assessment No. 146, AHRQ Publication No. 07-E002, Agency for Healthcare Research 
and Quality, November 2006; available at www.ahrq.gov/downloads/pub/evidence/pdf/cyp450/cyp450.pdf.
§ Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group, “Recommendations from the EGAPP Working Group: 
testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors,” Genetics 
in Medicine, 9, no. 12 (December 2007): pp. 819–825.
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for safety reasons, pharmacogenomics could potentially lead to relabeling 
and approval of these products for populations whose genotypes indicate 
they would benefit from, or not be harmed by, the drug. Finally, a better 
understanding of how genetic variations affect specific disease processes 
and drug responses may help identify new targets for drug development. 
Many see this as the ultimate promise of pharmacogenomics. 
challenGeS 
Pharmacogenomics carries great promise; however, the degree to which 
that promise is realized will depend on effective implementation of myriad 
steps and policy decisions that must be made by a variety of organizations 
in both the public and private sectors. 
Basic research 
The most obvious hurdle for pharmacogenomics is the complexity of the 
underlying science. The sequencing of the human genome, completed in 
2001, and the HapMap (see text box), completed in 2007, has given scientists 
a “parts list” and a companion catalogue of variations for the workings of the 
genome. However, the key to fully exploiting the potential of pharmacogenom-
ics is understanding how 
the relationships among 
genes, disease processes, 
drugs, and environmen-
tal factors work at the 
molecular level, and that 
understanding is still very 
rudimentary. Some genes 
(or their products) and 
the drugs that affect them 
are relatively well under-
stood, but they are the 
exception, not the norm. 
Indeed, many believe 
that the handful of ge-
netically targeted drugs 
already on the market 
are the “low-hanging 
fruit”; most involve sin-
gle genes (“mongenic”) 
whose influence was dis-
covered (sometimes by 
accident) after the drug 
was already in use. In 
contrast, most important 
biological processes are 
Deciphering  
Genetic variation
There are roughly 22,000 genes amidst the 3 billion 
DNA “bases” (designated by the letters A, T, C and 
G) that make up the human genome (see illustra-
tion, page 4). While more than 99 percent of those 
DNA bases are identical from person to person, there are still an estimated 
10 million single-letter variations—called single nucleotide polymorphisms 
(SNPs, pronounced “snips”)—in the human genetic sequence. Most of these 
variations are believed to be biologically insignificant, but a small fraction of 
them are known to alter the function of a gene—often only slightly, but some-
times significantly. The effect of many slightly altered genes interacting with 
each other, combined with environmental factors, may lead to increased risk 
for a particular disease or shift a biochemical pathway normally targeted by 
a drug. Scientists have mapped (the “HapMap”) where SNPs tend to occur in 
the genome.* However, the arduous process of deciphering which variations 
(and combinations) account for what biological effects, including drug effects, 
is immensely complex and has only just begun.†
* David A. Hinds et al., “Whole-Genome Patterns of Common DNA Variation in Three Human Populations,” 
Science, 307, no. 5712 (February 18, 2005): pp. 1072–1079; and International HapMap Consortium, “A 
second generation human haplotype map of over 3.1 million SNPs,” Nature, 449 (October 18, 2007): pp. 
851–861.
† Genome-wide association studies (GWAS) represent a powerful approach to detecting associations between 
genetic variants and common diseases, however, such studies are not designed to discover the specific mecha-
nisms involved. If an association is confirmed, its effect generally must be elucidated using different techniques. 
For information on NIH-supported GWAS, see www.genome.gov/20019523.
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governed by several genes (“polygenic”) and are often the result of varia-
tions in those genes interacting with each other and with something in the 
environment. How a person responds to a particular drug, for example, 
can be influenced by variables such as diet, other medications, and other 
underlying conditions, in addition to his or her particular set of genes. 
The cost and technical challenges of putting together the infrastructure 
needed to support research on the scale required to discover and charac-
terize genetic influences within complex interactions are enormous. Given 
so many variables, association studies and clinical trials need to enroll 
large numbers of participants and be supported by robust information 
management systems that can adapt to upgrades in the methods of ge-
nomic analysis.9 Moreover, while investment in genomic technologies has 
driven costs down significantly over the last decade,10 it is still expensive 
to sequence and analyze the amount of genetic material needed to pin-
point gene-drug-disease interactions. Once a specific genetic influence is 
determined, additional work is needed to explain the molecular pathways 
and mechanisms of action. Few individual institutions have the resources 
to mount such studies, so collaborations are a must.11 
co-Development of Pharmaceuticals and Genetic tests
One major challenge for both industry and regulators will be integrating 
genetic testing into drug development, approval, and marketing. The de-
velopment of a genetically targeted drug will require the development of 
an associated genetic test, first to locate the gene target for drug develop-
ment and then to identify patients who possess the targeted gene variant 
and therefore are candidates for the new therapy. As a practical matter, few 
pharmaceutical companies have expertise in the diagnostics business. The 
two industries have evolved separately, with distinct cultures, regulatory 
mechanisms, product lifecycles, and commercialization pathways. There-
fore, drug companies that wish to pursue pharmacogenomics as part of 
their drug development strategies will have to either learn diagnostics or 
partner with companies that already know the field. In addition, regula-
tors and third-party payers will need to develop policies to ensure that 
clinically validated genetic tests needed to inform prescribing of approved 
pharmacogenomic drugs are appropriately promoted with the drug and 
are accessible to physicians and their patients.
translating research into treatment
Research to discover associations between genes, disease, and drugs will 
be of little practical value without an understanding of how those find-
ings should translate into actual treatment decisions. For example, as 
noted above, doctors now know that an individual’s response to warfarin 
therapy is partially but significantly influenced by two genes, and a test 
is available to detect whether a patient has slow or fast metabolizer vari-
ants of these genes. However, knowing which genetic variants a patient 
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has does not tell the physician how to adjust the warfarin dose. Should 
doses be smaller? Should there be more time between them? Or should 
a different anticoagulant therapy be used? Further complicating matters, 
these genes explain less than half of the observed variability in patients’ 
responses to standard warfarin dosing.12 What other factors—genetic or 
otherwise—should be considered in making a dosing decision? In fact, 
gene-based dosing guidelines have not been developed for warfarin13 or 
any other CYP-metabolized drug because there is, as yet, no clear under-
standing of the optimal doses for slow or rapid metabolizers. Moreover, 
the rate at which the body clears a drug, and thus the likely corresponding 
adjustment to dose, varies by drug. This variability also applies to predict-
ing side effects and drug interactions. Finally, the effects of the same genetic 
variant may be quite different in different populations, again reflecting the 
interplay of many variables. Thus, each drug must be studied individually 
across multiple groups,14 which is a massive undertaking.
health information technology
Basic, translational, and clinical research and applications in pharmacoge-
nomics will require the sharing, storage, and management of massive 
amounts of information across multiple organizations and institutions, 
from the U.S. National Institutes of Health (NIH) and industry gene data-
bases to point-of-care decision support tools.15 Information technology 
systems will need operating rules and a common nomenclature that can 
accommodate the types and level of detail of pharmacogenomic-related 
data collected in different settings (the research center, the lab, the clinic, 
the surveillance registry, etc). Computational and analytic methods also 
will need to embrace bioinformatics (from the genomic testing) and clinical 
informatics (clinical trials and health care data).
Pharma Buy-in 
Until recently, most large pharmaceutical companies, which control the 
lion’s share of capital for pharmaceutical research and development, have 
been ambivalent about making significant investments in pharmacogenom-
ics. Some pharmaceutical executives worry that by segmenting diseases 
and patient populations, pharmacogenomics could shrink the market for 
“blockbuster drugs” that are the bedrock of the industry.16 In addition, 
because the traditional pharmaceutical business model generally depends 
on mass advertising and billion dollar sales, many experts believe these 
companies simply could not be successful developing drugs that serve 
only a small portion of the population. 
However, the number of profitable drugs coming off patent, shrinking drug 
pipelines, and persistent (and expensive) consumer and regulatory concerns 
over drug safety are forcing many pharmaceutical makers to reassess their 
current research methods and business portfolios. Most pharmaceutical 
companies now routinely collect pharmacogenomic data from their clinical 
until recently, most 
large pharmaceutical 
companies have been 
ambivalent  about 
making significant in-
vestments in pharma-
cogenomics. 
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trial participants for exploratory in-house analysis, and many have begun 
to invest in building capacity for pharmacogenomics to support at least a 
portion of their future drug development work. However, a sustained in-
dustry commitment to pharmacogenomics research and development will 
hinge on many variables, including the economics of “mini-buster” drugs 
and well-aligned regulatory pathways for each stage. 
cost
New pharmacogenomic therapies are likely to be expensive. Many of the 
drugs will be biologics (drugs made from human or animal proteins), 
the fastest-growing and most expensive group of drugs on the market. 
Moreover, both biologics and traditional “small molecule” drugs that are 
developed or approved for a genetically defined subpopulation or subcat-
egory of disease are likely to occupy the high end of the pricing spectrum. 
A treatment course of Herceptin, for example, can cost upward of $60,000. 
Manufacturers argue that premium prices are justified in exchange for the 
lower risk and higher certainty that these drugs will work in their target 
populations, and that less wasted drug use—that is, less use of drugs on 
patients for whom the drug has no effect or serious side effects—would 
help offset higher prices. Manufacturers also point out that a drug created 
for a limited market still needs to generate enough revenue to offset its 
development costs. 
Genetic tests also are expensive (between $200 and $3,500) and could be-
come more so even though the cost of the technology is expected to decline. 
Genetic test manufacturers are beginning to challenge the practice of “cross 
walking” new tests to old tests in order to establish fees, arguing that new 
diagnostics should be reimbursed based on the value of the information 
provided by the test. There are no standards or mechanisms to determine 
the “value” of new tests (though some have been proposed).17 However, 
the maker of a new prognostic test for early-stage breast cancer reasons 
that the $3,500 price tag is just one-quarter of the cost of chemotherapy for 
that condition, and that it will detect and avoid unnecessary chemo for the 
estimated 85 percent of patients whose breast cancer will not recur after 
surgery.18 Tests such as microarrays or “gene chips” that detect variations 
in multiple genes or gene products at one time are also potential cost driv-
ers. Although the tests themselves may not be very expensive, like all tests, 
they will produce some false positives that will then take additional testing 
and resources to rule out. And the opportunity for false positive findings 
is amplified when many genes are tested simultaneously. One group of 
researchers dubbed this phenomenon the problem of the “incidentalome.”19 
There is also the possibility that these tests could find true positives or 
turn up other information—for example, a genetic predisposition to a 
particular form of heart disease—that were not part of the original reason 
for seeking the test but could lead to expensive medical interventions or 
prophylactic drug regimens. These costs may be warranted, but they are 
added costs nonetheless.
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Demonstrating value
Pharmacogenomic technology will only move forward if developers are 
confident that the market is robust enough to justify the investment. The 
market for pharmacogenomic (and most other) therapies is mediated by 
third-party payers who will want proof that these therapies add value to 
health care by holding or reducing costs and improving outcomes—proof 
that is currently missing and that will take time and resources to develop. 
A widely cited literature review turned up just 11 cost-benefit analyses of 
pharmacogenomic interventions, covering a limited range of conditions 
with mixed results.20 Today a few of the largest health care organizations, 
such as Kaiser Permanente, Aetna, and Partners Health Care, are studying 
whether and how they should incorporate pharmacogenomics into their 
clinical processes. They are examining parameters like the cost of a phar-
macogenomic test, mortality due to adverse drug reactions, prevalence of 
the particular genotype being targeted by the test, and whether test results 
would change providers’ clinical decisions in ways that improve patient 
outcomes—all key to establishing the value of a pharmacogenomic approach 
to prescribing a particular drug. These early assessments, in turn, will help 
determine how much incentive developers have to invest in this arena and 
where their energies would be best directed. 
feDeral initiativeS 
Federal health agencies have undertaken a number of initiatives to facili-
tate the progress of pharmacogenomics. These include significant funding 
and organizational support for public-private sector research networks 
designed to broadly share data and research tools, a consultative approach 
to evolving new regulations, and efforts to create evaluation methods for 
the clinical applications of this developing technology.
The nih, the nation’s primary driver of basic biomedical and genetics re-
search, has launched several major projects specifically to help genetics 
researchers find meaningful associations between genetic variations and 
drug response among the 10 million common variations in the human ge-
nome. The Pharmacogenetics Research Network (PGRN) is a nationwide 
collaboration of scientists created specifically to study the effects of genes 
on individuals’ responses to medications, including drugs for asthma, de-
pression, cancer, and heart disease.21 The Genetic Association Information 
Network (GAIN) is a public-private partnership that provides industry 
and academic researchers access to tissue samples from NIH clinical trial 
participants for genetic association studies. A primary objective of the NIH 
is to place as much genomic data and research technology as possible in the 
public domain, making it accessible to the global research community.
The fDa sees pharmacogenomics as both a tool to help achieve its mission of 
ensuring that drugs are safe and effective and as an opportunity to advance 
its Critical Path Initiative, which aims to help drug (and other medical prod-
uct) development keep pace with advances in biomedical research.22 The 
third-party payers will 
want proof that these 
therapies add value to 
health care by holding 
or reducing costs and 
improving outcomes.
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agency has been spearheading discussions with industry about all aspects 
of pharmacogenomics and the research and regulatory approaches that 
can best promote it.23 FDA and the Arizona-based C-Path Institute,24 a new 
private foundation with which FDA collaborates, are coordinating research 
consortia that include some of the nation’s largest drug manufacturers as 
well as academic researchers to develop new targets (biomarkers) and 
research tools for pharmacogenomics and to share preclinical and clinical 
research methods and data that may be relevant to assessing drug safety. 
The FDA has also developed a Voluntary Genomic Data Submission process 
to encourage companies to share data on exploratory genetic biomarkers 
they are collecting from clinical trial participants without fear that these 
data will be used to delay approval or make it conditional.25 New rules for 
“adaptive” clinical trials permit genetic “enrichment” of the study popula-
tion as a trial proceeds in order to reduce the time needed to demonstrate 
a new drug’s safety and effectiveness.26 For companies that want to market 
a drug specifically to a genetic subset of patients, the FDA is refining a pro-
cess and standards for coordinated review and approval of the drugs and 
their associated genetic tests, which currently are regulated differently by 
separate Centers within the agency.27 Finally, the FDA is negotiating what 
pharmacogenomic information must be included on specific drug labels 
where evidence of gene-drug interactions is conclusive.
The centers for Disease control and Prevention (cDc) and the agency for 
health care research and Quality (ahrQ) support a number of programs 
that potentially could answer questions about the value of pharmacoge-
nomics that clinicians, health plan administrators, policymakers, and 
patients will be asking as more applications become available. The CDC 
created the Evaluating Genomic Applications in Practice and Prevention 
(EGAPP)28 initiative to develop an evidence-based method for judging the 
usefulness of specific genetic and pharmacogenomic tests as they transi-
tion from research into clinical practice. So far, EGAPP has completed four 
of six planned evidence reviews, three of which remarked on the lack of 
high-quality clinical studies to determine whether the tests affect patient 
management decisions in ways that improve outcomes (some tests were 
still investigational at the time of EGAPP’s review, so such studies may be 
forthcoming). AHRQ spearheads a network of Evidence-Based Practice 
Centers that conduct assessments of health care services and technologies, 
including the specific pharmacogenomic applications of interest to EGAPP. 
In addition, AHRQ conducts research “to advance the optimal use of drugs, 
medical devices and biological products” through its Centers for Education 
and Research in Therapeutics (CERTs),29 which the agency operates with the 
FDA. CERTs could incorporate pharmacogenomic tests into their analyses 
of factors that influence the effectiveness of specific drug therapies. Finally, 
AHRQ’s Developing Evidence to Inform Decisions about Effectiveness 
(DEcIDE) program taps electronic health information databases to conduct 
rapid turn-around studies on health services outcomes and comparative 
effectiveness; such studies could be instrumental in identifying priorities 
for pharmacogenomics clinical research. 
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Policy iSSueS 
How quickly pharmacogenomics develops into a useful clinical toolkit 
will depend greatly on how policymakers respond to policy issues 
associated with both genetic testing and targeted drug development, 
including concerns about safety, access, cost, and potential ethical and 
social implications.
Safety and Quality 
Pharmacogenomics depends on the availability and reliability of genetic 
tests to accurately detect selected genetic markers that are important to drug 
therapy decisions as well as the ability of providers to interpret test results 
in order to make safe and appropriate use of targeted therapeutics. There is 
considerable debate over whether current resources and regulatory require-
ments are adequate to ensure the safety and quality of genetic testing.30 
Genetic tests — Regulatory oversight of genetic testing is spread across the 
FDA, the Centers for Medicare & Medicaid Services (CMS), and the CDC. 
FDA regulates “test kits” (that is, stand-alone tests that are produced, pack-
aged, and sold with all ingredients and instructions necessary to conduct 
the test) as in vitro diagnostic devices (IVDs) that must be approved for 
safety and effectiveness before they can be marketed. Today, however, most 
genetic tests are not sold as test kits. They are created more or less from 
scratch by the clinical laboratories that offer them and have been consid-
ered to be medical services provided by the lab rather than commercial 
products. Historically, these so-called “home brew” tests have not been 
reviewed by FDA. As a result, of the more than 1,200 genetic tests clinically 
available,31 fewer than a dozen have been developed as IVDs and approved 
by the FDA, leaving the majority of genetic tests without any independent 
external review of their analytic or clinical validity before they are offered 
to the public.32 As genetic testing technologies grow more complex, many 
argue that FDA oversight should extend to laboratory-developed genetic 
tests in order to validate the proprietary testing methods, ensure test accu-
racy and appropriate labeling, provide a means of postmarket monitoring, 
and level the regulatory burden for manufacturers who do go through the 
effort of developing FDA-approved test kits.33 Indeed, FDA has recently 
issued draft regulatory guidance for one new type of laboratory-developed 
genetic test called a Multivariate Index Assay (MIA),34 which uses complex 
proprietary formulas to calculate the odds of a particular health outcome 
based on an individual’s genetic profile. The FDA is assessing whether it 
has the resources to actively oversee other categories of lab-developed 
tests; however, opponents argue that FDA review of home-brew type tests 
would be an intrusion into the practice of laboratory medicine and would 
add costs and delays to bringing new tests to market.35 
Genetic testing laboratories — CMS and the CDC share responsibility for 
ensuring the quality of testing laboratories under the Clinical Laboratory 
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Improvement Amendments of 1988 (CLIA). 
CLIA specifies standards for laboratory quality 
assurance and mandates specialty certifica-
tion and proficiency testing for laboratories 
that perform certain highly complex tests. 
Proficiency testing measures a laboratory’s 
actual performance on test procedures and 
is a key element in determining laboratory 
competence. Under CLIA, genetic tests are 
considered highly complex, but CLIA regula-
tions—written when genetic testing was still 
in its infancy—have not been updated to 
mandate proficiency testing standards for ge-
netic testing.36 Currently, most labs performing 
genetic testing participate in some level of pro-
ficiency testing through programs offered by 
private organizations, but such participation 
is voluntary and not universal. To address the 
gaps, the CDC’s Clinical Laboratory Improve-
ment Advisory Committee announced plans 
in 2000 to create a genetic testing specialty 
under CLIA,37 and a proposed rule was placed 
on the regulatory agenda of the U.S. Depart-
ment of Health and Human Services (HHS) 
for late 2006.38 Before the rule was issued, 
however, CMS reversed course, stating that it 
believes genetic testing is adequately covered 
by existing CLIA standards. Several influential 
genetics policy and patient advocacy organiza-
tions objected to CMS’s reasoning and filed a 
“citizen’s petition,” insisting that the agency 
create standards for and mandate participation 
in proficiency testing programs for genetics.39 
A draft report by the Secretary’s Committee on 
Genetics, Health and Society (SACGHS) like-
wise recommended that the HHS take specific 
steps to increase the use of proficiency testing 
for genetic tests.40 
Provider capacity — To use pharmacogenom-
ics appropriately in patient care, clinicians 
must understand exactly what information 
a given test can and cannot provide, how to 
interpret positive and negative test results, and 
what medical management options are avail-
able. Studies show that many health care pro-
viders are not prepared to make appropriate 
use of genetic tests. In one survey, 72 percent 
Some genetic tests are now 
being sold over the Inter-
net, prompting widespread 
debate about the appro-
priateness of marketing genetic tests directly to con-
sumers. Though some believe that direct-to-consumer 
(DTC) marketing of scientifically validated genetic tests 
can empower consumers and encourage patients to 
engage their physicians in a dialogue about their health 
care, others argue that without the help of a qualified 
health care provider to interpret test results, DTC ge-
netic tests can be difficult to understand at best and 
useless or harmful at worst.* In addition, a recent U.S. 
Government Accountability Office (GAO) investigation 
found evidence that some companies are capitalizing 
on consumer interest in genetics by selling less-than-
trustworthy tests. The genetic tests in GAO’s study 
were designed to get consumers to buy expensive food 
supplements “personalized” to their DNA,† but there 
is nothing to stop a company from offering genetic tests 
for more “serious” health-related conditions directly to 
consumers,‡ whether or not the test has been reviewed 
by the FDA or is performed in a CLIA-certified labora-
tory. For that reason, the Federal Trade Commission 
and the FDA together issued a consumer alert about 
DTC genetic tests, while the GAO echoed calls for more 
thorough regulatory oversight of genetic tests to ensure 
that consumers “have reliable information in order to 
determine which tests are accurate and useful.”
* American College of Medicine Genetics Board of Directors, “ACMG Policy 
Statement on Direct-to-Consumer Genetic Testing,” Genetics in Medicine, 
6, no. 1 (January/February 2004): p. 60; available at: www.acmg.net/resources/
policies/Direct_Consumer_Testing.pdf.
† Gregory Kutz, U.S. Government Accountability Office (GAO), “Nutrigenetic 
Testing: Tests Purchased from Four Web Sites Mislead Consumers,” GAO-
06-977T, testimony before the Special Committee on Aging, U.S. Senate, July 
27, 2006; available at http://www.gao.gov/new.items/d06977t.pdf. The GAO 
investigation found that companies purporting to analyze an individual’s 
genetic information for personalized nutritional and lifestyle recommenda-
tions generally provide the same advice—such as adopting a healthy diet and 
avoiding smoking—available from many other sources, but that some go on to 
recommend the same “tailored” dietary supplement, costing as much $2,000 
per year, to all customers which contains vitamins obtainable at a drug store 
for around $35. 
‡ Stephen Barrett and Harriet Hall, “Dubious Genetic Testing,” Quack Watch, 
April 9, 2002; available at www.quackwatch.org/01QuackeryRelatedTopics/
Tests/genomics.html.
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of nongeneticist physicians rated their own knowledge of genetics as fair 
to poor.41 In another study, physicians misinterpreted genetic test results 
in nearly one-third of colon cancer cases.42 Such statistics have prompted 
calls to revamp provider educational curricula at all levels to emphasize 
genetic medicine. However, many doubt that individual providers, particu-
larly busy primary care physicians, will have the interest or the capacity 
to become well-schooled in genetics. Rather, they suggest, this is where 
professionally developed clinical guidelines—developed by appropriate 
specialists or specialty societies and independently reviewed—could prove 
valuable to practicing clinicians. Several groups have called on the federal 
government to create a mechanism for prioritizing and funding clinical 
genetic guideline development. Genetic testing laboratories may also 
have a role in ensuring that physicians are able to request and interpret 
pharmacogenomic tests appropriately. The National Academy of Clinical 
Biochemistry has drafted guidelines recommending that laboratories that 
conduct pharmacogenetic testing either have a consultation component 
available to provide physicians with a complete interpretation of test re-
sults, or work with an organization that can provide such services.43
A complementary approach to ensuring provider competence with phar-
macogenomics calls for strengthening the dedicated genetics work force. 
Medical geneticists and genetic counselors in particular can serve as bridg-
ing professions for nongeneticist physicians, laboratories, and pharmacists. 
However, there are only about 3,100 professionals in the United States 
who are specifically trained and certified to provide genetic counseling 
and clinical genetic services (and the counselors themselves would need 
special training in pharmacogenomics), prompting calls to grow the field 
with reimbursement or other practice incentives.44 
Drug trials, “off-label” prescribing, and postmarket surveillance — The 
very precision that characterizes pharmacogenomics could raise new 
concerns about drug safety. Pharmacogenomics makes it possible to “en-
rich” clinical trials with individuals whose genotype suggests that they 
will respond well to the drug under study, thereby more quickly demon-
strating a drug’s efficacy and reducing the potential for adverse reactions 
during the trial. However, enriched clinical trials weighted with “good 
responders” may not reveal potentially harmful or toxic effects of the 
drug in other populations. FDA requires drugs that have been tested in 
defined populations or for specific conditions to be labeled for use only in 
those circumstances, but it is well-known that doctors very often prescribe 
drugs off label—that is, in doses or situations for which the drug has not 
been formally approved. 
Physicians prescribe drugs off label for a number of reasons. New off-label 
treatments can be grounded in top-notch research that is comparable to the 
rigorous studies that the FDA would demand, but they can also be sug-
gested by poorly designed studies, anecdotally by a physician colleague, 
or even by a pharmaceutical company representative.45 Sometimes, a 
physician’s impetus for off-label prescribing is simply professional hunch 
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that may lead to important new indications for a drug; at other times, it is in 
response to patient demand for a highly touted therapy, particularly when 
there are few acceptable alternatives. Herceptin, one of the first pharma-
cogenomic drugs, is effective (and labeled) only for patients whose breast 
cancer tumors overexpress the HER2 gene, but doctors have prescribed 
it for patients without that mutation. In this case, the patient is unlikely 
to receive any benefit from this very expensive drug. 46 More worrisome 
is the potential that drugs developed to treat or avoid toxicities and/or 
adverse reactions in people with a specific genotype could be problematic 
and possibly even dangerous when prescribed off label to someone with 
a different genotype. 
Given these concerns, some have suggested the need for a firmer approach 
to managing off-label prescribing, including restrictions on the clinical 
use of targeted therapies and tests, enhanced state requirements for phy-
sician compliance with product labeling, or the required involvement of 
licensed pharmacogenomics counselors in certain types of prescribing 
decisions.47 The FDA was given expanded authority under the Food and 
Drug Administration Amendments Act of 2007 to impose Risk Evaluation 
and Mitigation Strategies (REMS) that could include such provisions if 
the agency can show that they are necessary to ensure that the benefits of 
a product outweigh the risks. However, mustering the level of evidence 
needed to support such a determination is fraught with challenges. In ad-
dition, monitoring compliance by health care providers and patients with 
any REMS safe-use provisions that FDA might require falls to the drug 
manufacturer, who may or may not be well-equipped for the role. 
Such safety concerns may also amplify the need for a comprehensive 
system of postmarket surveillance. The current Adverse Event Reporting 
System (AERS), through which clinicians and companies are supposed 
to report serious and unexpected events that occur once a drug is mar-
keted, receives no more than 10 to 25 percent of actual adverse events,48 
making it difficult to identify patterns in a timely manner. A recent report 
by the Institute of Medicine on drug safety and public health49 recom-
mends that the FDA strengthen its postmarket surveillance activities by 
making better use of existing data sources, such as Medicare claims and 
large health maintenance organizations (HMOs) that have computerized 
systems for tracking such events. The FDA Amendments Act implements 
this recommendation and also gives the FDA more authority to require 
new studies or clinical trials of drugs flagged by the surveillance system. 
Greater use of electronic health records (EHRs), which would provide 
important clinical context for adverse drug events, along with the collec-
tion and genetic testing of DNA samples as part of adverse event report-
ing (with the samples to be deposited in a national registry accessible for 
pharmacogenomic association studies) are other possible approaches to 
bolster postmarket drug safety. The success of any approach, however, 
will depend on whether the FDA is provided sufficient resources to sup-
port active surveillance and timely response.50 
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making current drugs safer — Most of the attention on pharmacogenomics 
has focused on its role in bringing future drugs to market, but the technology 
could also be used to identify genetic risk factors for adverse drug reactions 
associated with drugs that have long been staples in American medicine 
cabinets.51 One study found that all but 3 of the 27 most commonly identi-
fied drugs in adverse drug reaction studies were among the top 200 selling 
drugs in the United States at the time.52 Reducing adverse reactions in just 
these drugs could have a large impact. However, manufacturers struggling 
to fill their pipelines have little incentive to invest in costly pharmacogenomic 
research to identify potential genetic contraindications for popular drugs 
already on the market. The FDA Amendments Act provides a mechanism 
for the agency to compel postapproval studies by the drug sponsor under 
specific circumstances53 but only if the agency becomes aware of a new 
safety problem with the drug. As a result, much of the research needed to 
illuminate pharmacogenomic properties of familiar, widely prescribed drugs 
may fall to federal agencies and academic institutions. 
access
Third-party coverage and payment decisions can speed adoption and 
use of new technologies or can create serious barriers to access. Health 
insurers, including Medicare, will need to consider coverage and reim-
bursement policies for genetic tests that are performed to guide prescrib-
ing decisions and for the drugs that are prescribed on the basis of those 
tests. Access to pharmacogenomic technology will also be influenced 
by incentives for companies to develop tests and therapies for smaller 
populations and for providers to integrate the technology into their 
clinical practices. 
coverage of pharmacogenomic tests — Insurers, including Medicare, 
make coverage decisions for new diagnostic tests on a case-by-case basis. 
Private health plans generally will cover pharmacogenomic tests when they 
are required or strongly recommended on an FDA-approved drug label, 
such as the HER2 test for Herceptin.54 Coverage of pharmacogenomic 
tests that are not required by a label varies, depending mostly on the 
plan’s assessment of whether the test is “medically necessary.”55 Medical 
necessity criteria usually include high-quality scientific evidence, prefer-
ably from clinical trials, that a given test or service is safe and effective 
in improving the diagnosis or management of disease at least as much 
as established alternatives.56 However, most pharmacogenomic tests are 
still too new to have been subjected to the kind of rigorous comparative 
effectiveness analysis that would meet the medical necessity threshold. 
Until they do, many pharmacogenomic tests are likely to be regarded as 
experimental and therefore not covered by private health plans. Notably, 
CMS and its local contractors have flexibility to extend conditional cover-
age to such tests under Medicare’s “Coverage with Evidence” policy (see 
text box, next page).
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In contrast to its flexibility to cover new diagnostic tests, Medicare’s 
medical necessity clause does not permit coverage of tests—genetic or 
otherwise—for preventive screening purposes (unless coverage of a 
specific test is mandated by Congress). Thus, genetic testing to identify a 
predisposition to a disease for which the patient has no signs, symptoms, 
or family history, would not be covered by Medicare.57 Private insurers 
generally cover screening tests, including some genetic tests that have 
been shown cost-effective in reducing disease burden on their population 
mix; however, pharmacogenomic tests are not yet able to prove value on 
a population basis.58 
coverage of pharmacogenomic drugs — Current drug coverage and cost 
control mechanisms may not work well for pharmacogenomics. For ex-
ample, formulary placement is key to any health plan’s ability to negotiate 
drug prices, guide drug use, and control spending. Formularies are built on 
the concept of “therapeutic equivalence” within drug classes, thus allowing 
the selection of a preferred drug and exclusion or penalties for substitution. 
Drug makers typically prefer formularies that are broken down into more 
classes or categories to increase the number of listed products, but payers 
prefer formularies that feature fewer drug classes and disease categories 
because they provide more negotiating leverage with manufacturers and 
distributors. Pharmacogenomics, however, is specifically intended to un-
cover clinically important therapeutic differences within drug classes and 
to identify new subcategories of disease based on genetic information. It is 
conceivable that, over time, pharmacogenomics could overwhelm efforts to 
contain the number of formulary disease categories and could create real 
pressure to expand preferred drug listings for genetic subpopulations. 
Medicare has adopted a coverage policy for promising new technologies called 
Coverage with Evidence Development (CED), under which CMS may opt to cover 
specific medical innovations—such as pharmacogenomic drugs and diagnostics—
that are too “young” to have accumulated the amount of clinical evidence required 
to meet the usual standard for coverage, which typically includes published results 
from several high-quality controlled clinical trials. CED can actually help develop 
that evidence base by linking Medicare coverage to a requirement that patients participate in a registry 
or clinical trial, which in turn could support a future decision about unconditional coverage.* A second 
element of CED, called “coverage with appropriateness determination,” allows CMS to approve coverage 
and reimbursement for an “experimental” new drug or service based on whether a patient has “appropri-
ate” indications (potentially including genetic test results indicating that the patient would respond well 
to a particular therapy), similar to private insurers’ use of prior authorizations.† Both of these options give 
CMS the flexibility to cover some pharmacogenomic therapies, potentially even before other payers, and 
in the process generate data on the clinical usefulness and cost-effectiveness of specific pharmacogenomic 
applications that could be mined by other researchers.
* Some policymakers and patient groups have challenged the ethics of linking insurance coverage to a requirement for participation in registries, saying 
such a requirement could be considered coercive. 
†  Sean R. Tunis and Steven D. Pearson, “Coverage Options for Promising Technologies: Medicare’s ‘Coverage With Evidence Development,’” Health 
Affairs, 25, no. 5 (September/October 2006): pp. 1218–1230.
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One frequently asked question is whether payers could limit coverage of 
certain drugs to patients whose genetic profiles indicate that they are likely 
to benefit from those drugs.59 Pharmacy coverage decisions generally fol-
low any relevant FDA policies or label indications. Roughly ten percent of 
currently marketed drugs have some pharmacogenomic information on 
the label,60 but only a handful go so far as to require genetic testing prior 
to prescribing the drug. Unless there is a very clear connection between 
test findings and prescribing decisions, the FDA is less likely to require 
the test on the label. Where the linkage appears clear, as in the case of Her-
ceptin, the FDA has required labeling and testing, and coverage policies 
have followed suit. Again, physicians can always opt to prescribe drugs 
off label (in this case, in the absence of the genetic test), if in their profes-
sional judgment the patient would benefit from the drug. However, unless 
a specific off-label use has become part of accepted medical practice or has 
been shown effective in high-quality studies, there is a good chance that 
a payer could deny reimbursement. 
reimbursement rates — Genetic tests generally are reimbursed under 
the same pathology CPT (current procedural technology) coding system 
and laboratory fee schedule as other laboratory tests. Payment amounts 
for new tests are linked to payment levels for existing tests based on the 
level of effort required to perform the test.61 (That is, whether a new test 
diagnoses a common virus or a complex pattern of genetic variations does 
not matter; if the two tests use the same laboratory technique, then they are 
reimbursed roughly the same amount.) When a test uses a breakthrough 
technology that has no precedent on the fee schedule, payers will conduct 
technology assessments to set reimbursement rates as they do for any other 
service. Currently, the Medicare laboratory fee schedule serves as the basis 
for many private insurers’ laboratory reimbursement schedules. However, 
the Medicare schedule was designed almost 20 years ago, and laboratory 
testing technology has evolved so much since then that most experts agree 
that the fee schedule amounts have little logical relationship to the services 
they cover. In other words, labs are undercompensated for some tests and 
may be overcompensated for others. The Medicare Modernization Act of 
2003 froze the Medicare laboratory fee schedule until 2009; many hope it 
will be comprehensively revised at that time. 
intellectual property — The pharmaceutical industry depends on intel-
lectual property law to protect its investment in innovation, but many are 
concerned that current gene patenting and licensing practices could raise 
the costs and slow the development of pharmacogenomic therapies.62 By 
patenting genetic sequences63 or methods to detect them, patent holders 
gain enormous control over all “downstream” commercial applications, 
including the right to keep others from developing a drug to target or a 
test to detect that gene.64 Multiple genes or regions of genes are usually 
involved in regulating drug response; if competing entities hold patents 
on any of those genes or regions, they could “block” each other from 
developing a pharmacogenetic test unless they are willing to enter into 
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a cross-licensing agreement. A report by the National Research Council 
found evidence that licensing and royalty fees are already deterring labo-
ratories from offering certain genetic tests.65 Laboratory directors have 
testified that up-front flat fees and per-test royalties typically demanded 
by licensing agreements add 15 percent or more to the cost of tests and 
that such costs are not factored into existing laboratory fee schedules.66 As 
pharmacogenomic tests become more complex and include more genes, the 
need to negotiate multiple patents and cross-licensing agreements could 
eventually make some tests too expensive or cumbersome for any but the 
biggest laboratories to offer. It has been suggested that new intellectual 
property concepts similar to patent pooling adopted in other industries 
may be needed to keep tests affordable and accessible.67 
* The Office of Rare Diseases at the NIH maintains a list of rare diseases and conditions at http://rarediseases.info.nih.gov/asp/diseases/diseases.asp.
† Paul D. Maher and Marlene Haffner, “Orphan Drug Designation and Pharmacogenomics: Options and Opportunities,” BioDrugs, 20, no. 2 
(2006): pp. 71–79.
‡ Jai Shah, “Economic and regulatory considerations in pharmacogenomics for drug licensing and healthcare,” Nature Biotechnology, 21, no. 7 
(July 2003): pp. 747–753.
§ “Novartis Drug Wins Expanded FDA Approval,” Associated Press, October 19, 2006.
As an incentive to drug companies 
not to overlook small markets, the 
federal Orphan Drug Act provides 
manufacturers who develop therapies for rare dis-
eases (those that affect fewer than 200,000 people) 
significant financial and marketing subsidies, 
including grants for research and development, 
“fast-track” approval, tax credits, non-negotiated 
pricing privileges, and a period of marketing 
exclusivity against competing products. The Act 
has been very successful, resulting in new drugs 
for over 200 rare diseases, and the FDA is actively 
encouraging drug companies to pursue pharma-
cogenomic approaches to more of the 6,000 remain-
ing orphan diseases identified by NIH.* However, 
from a regulatory standpoint, pharmacogenomics 
could upend disease classification schemes and 
basic assumptions about what constitutes a rare 
disease.† Many relatively common diseases, like 
breast cancers, can now be subdivided on the ba-
sis of genomics into distinct and sometimes rare 
subtypes that require different drug therapies. It 
is just as possible that diverse rare diseases may 
turn out to share molecular genetic disease process 
that are amenable to the same drug.‡ For example,  
Novartis was able to secure orphan 
status for Gleevec on the grounds 
that the drug was indicated for 
a population of approximately 40,000 chronic 
myeloid leukemia patients with a particular chro-
mosomal abnormality. However, Gleevec has since 
been shown useful in treating a rare gastrointes-
tinal tumor that has a mutation in a different but 
related gene, and in October 2006 it was approved 
to treat yet another type of tumor as well as four 
rare blood diseases.§ Additional indications for the 
drug likely will be found that are driven by a com-
mon set of genes. Given the significant incentives 
conferred by the Act, drug developers may find it 
attractive to submit drugs whose initial application 
would qualify for orphan drug status even before 
formally testing the drug for different indications 
that may share the same underlying mechanism. 
At some point, understanding these mechanisms 
could lead to a redefinition of rare disease; in the 
meantime the FDA will need to strike a careful 
balance between encouraging orphan drug ap-
plications to stimulate risky pharmacogenomics 
research and ensuring that those applications 
remain consistent with the intent of the Act.
orphan Drugs
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Physician uptake — Despite its apparent advantages over trial-and-error 
prescribing, pharmacogenomics will probably not be embraced by physi-
cians in the absence of significant incentives to compensate for the extra 
time and education that will be needed to integrate this technology into 
their practices. Many physicians consider their diagnostic skills and pre-
scribing decisions part of the “art” of medicine and will demand convincing 
evidence that information from genetic test results adds clinical value and 
leads to better outcomes for their patients. From a physicians’ perspective, 
pharmacogenomics may only complicate prescribing and drug dispensing 
by requiring an extra diagnostic step that includes additional paperwork, 
delays in care while waiting for the laboratory report, and longer patient 
visits to explain the complex results. Past experience in trying to change 
physician practice patterns, for example, to improve rates of preventive 
services and encourage adoption of electronic medical records, has demon-
strated the need to provide strong incentives through reimbursement and 
performance feedback. However, creating appropriate practice incentives 
for pharmacogenomics could be very challenging given already daunting 
budgetary issues in Medicare Part B and competing priorities in quality 
and performance measurement systems. 
cost
It is often asserted that pharmacogenomics will produce cost savings to 
the health care system through better patient care and reduced drug de-
velopment costs. These claims are difficult to evaluate at this early stage of 
the technology’s development. It is also possible that pharmacogenomics 
could contribute to increasing health care costs. 
Important sources of potential cost savings include a reduction in the num-
ber of adverse drug reactions that not only place patients in danger but 
often result in emergency room visits and expensive rehabilitative care,68 
as well as the development of more effective therapies that require fewer 
return visits to physicians (and free up health care resources). For example, 
a recent effort to model savings from integrating genetic testing into routine 
warfarin therapy concluded that warfarin users in the United States would 
avoid 85,000 serious bleeding events and 17,000 strokes annually and save 
$1.1 billion each year.69 If pharmacogenomics enables doctors to prescribe 
more accurately and results in faster, more effective therapy with fewer side 
effects, it could indeed deliver savings throughout the health care system. 
Supporters also anticipate cost savings from streamlining drug develop-
ment. The Boston Consulting Group estimates that targeted drug devel-
opment techniques could shave up to $335 million and two years off the 
cost of bringing a new drug to market, mostly through shortening the time 
needed for clinical trials.70 
On the other hand, there are reasons to be skeptical that pharmacoge-
nomics will be able to reduce health care costs overall. First, in order 
to significantly reduce the number of ineffective therapies and adverse 
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drug reactions, genetic testing and targeted prescribing would have to 
be widely deployed, and as noted earlier, there is little incentive for drug 
manufacturers to undertake the expense of developing or promoting 
pharmacogenomic tests for drugs that are already on the market. Public 
sector efforts, such as the PGRN and EGAPP have stepped in to develop 
and synthesize the scientific and clinical research base for some of the most 
often implicated drugs, but these efforts will take time. Getting specific 
findings, including pharmacogenomic testing and prescribing guidance, 
into the hands of receptive physicians and other health care professionals 
remains a challenge.
Second, most experts anticipate that companies will 
demand higher prices per unit of pharmacogenomi-
cally tailored drugs to make up for the smaller potential 
market. Indeed, companies already have demonstrated 
that they are willing to set and hold premium prices for 
pharmacogenomic tests and targeted therapeutics, even under intense 
public criticism.71 Moreover, new pharmacogenomic drugs will be patent-
protected from generic competition for many years. Some suggest that the 
very biological precision that enables the new targeted drugs to command 
high prices will enable would-be competitors to “invent around” patented 
products by targeting different molecules in the same disease pathway, 
or by targeting the same molecule using a different mode of action.72 So 
far, however, there is little evidence from today’s drug marketplace that 
inventing around will put any significant downward pressure on price.
Third, whether pharmacogenomics will reduce the cost of clinical trials is 
still an open question. Currently, clinical trials in which subjects’ genetic 
variations are taken into consideration may be more expensive to operate 
than those trials where no genetic data are used.73 According to a trade 
publication, “There is no question that applying pharmacogenomics to 
clinical trials increases the cost. There is added cost in the preclinical stages, 
where biomarkers must be identified and validated. Then there is extra 
cost in the clinic, where study design needs to take genetics into consider-
ation….Using a pharmacogenomic approach could even slow down clinical 
trials if you must seek out a patient population that is enriched for your 
trial.”74 Over the longer term, as technologies for identifying biomarkers 
and managing patient information evolve, it is possible that some of these 
costs may come down,75 and it is possible that such trials will indeed be 
shorter, enabling the hoped-for savings in comparison to traditional trials. 
Whether overall savings are achieved will likely depend on the relative 
proportion of targeted (versus blockbuster) drug candidates for whom 
streamlined trials are appropriate.
Fourth, although pharmacogenomics may create opportunities to “rescue” 
failed drugs, it remains to be seen whether and under what circumstances 
pharmaceutical companies will find that option economically viable. Because 
intellectual property claims are filed long before regulatory approval, there 
will likely be limited life remaining on the original drug, compounded by 
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the additional time involved for further testing that the FDA likely would 
require.76 One possible scenario is illustrated by the multiple sclerosis drug 
Tysabri, which was pulled from the market in 2004 after concerns about a 
potentially dangerous side effect. The drug was reintroduced a year later 
with a label for a smaller population, a controlled distribution system to 
ensure that it is only given to patients for whom the risk is justified, and a 
price increase of 21 percent (to $28,400 per year).77 
Fifth, it is possible that this technology can be used to exploit incentives 
in the current drug approval and reimbursement systems in ways that 
raise costs for consumers and the health care system overall. For example, 
as noted previously, health plans pay for drugs according to formularies 
that attempt to control costs by including a limited number of therapeuti-
cally equivalent drugs and negotiating pricing on the basis of formulary 
placement and tiering. However, if a drug maker can show, using phar-
macogenomics techniques, that a particular drug produces a statistically 
better result (even if only marginally so) for a genetically defined group of 
patients, it may be able to differentiate a “me too” product into a “me only” 
drug, creating pressure to include it on the formulary at least for that group 
of patients.78 As one pharmaceutical company executive has noted, “Even 
average drugs can become ‘superdrugs’ in the right population.”79 
Finally, some worry that pharmacogenomics will add costs without adding 
value. For example, very expensive drugs could be used in populations or for 
indications beyond those for whom they are designed, as has happened with 
Herceptin. Test-drug combinations may not produce clinically meaningful 
improvements in patient outcomes over current therapies. Or genetic testing 
could turn up lots of potentially “abnormal” results that are not clinically 
relevant but that would require massive additional resources to rule out. In 
the absence of comparative effectiveness and cost-benefit data that can assess 
the value of this technology as it evolves, such developments could be very 
challenging for policymakers and health care institutions to manage. 
In addition, pharmacogenomics will certainly add direct service costs for 
genetic testing, data collection and analysis, and counseling. One expert 
summarized the issue this way: “It will be more cost effective, but it will 
not be cost saving. So you’ll pay more and you’ll get more, but you will 
not save money.”80 
ethical considerations
The ethical, legal, and social implications of pharmacogenomics have been 
widely acknowledged. In particular, issues associated with personal ge-
netic data collection, use, and interpretation will require careful handling 
by policymakers.
Patient privacy — Many believe that statutory protection against dis-
crimination on the basis of genetic information is an essential condition 
for pharmacogenomics to succeed. It is well documented that people will 
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hesitate or even refuse to participate in genetics research, take advantage 
of potentially helpful genetic tests, or disclose medical history informa-
tion if they fear their data could be misused or their privacy violated. In a 
2003 study on hereditary colon cancer, 39 percent of patients identified the 
potential effect on their health insurance as the most important reason not 
to undergo genetic testing to find out if they carried one of several known 
predisposing genes for the disease.81 Other observers have argued that it is 
unreasonable to single out genetic information for special protection given 
all the other biological sources of potential stigma, such as HIV status.
Guidelines for sample collection and storage — To be ethically valid, re-
quests for patient consent to use identifiable biological samples in research 
must be clear about the purpose of the research, how the samples will 
be used, and who will have access to them. If these parameters change, 
patient consent must often be obtained again. What are the appropriate 
standards for security, access, and informed consent when patient DNA 
samples are being gathered as a routine part of clinical trials and stored 
for future exploratory analysis? 
collateral information — While pharmacogenomic tests to inform prescrib-
ing decisions may not be as sensitive per se as other types of genetic tests, 
it is possible that testing will turn up additional information about disease 
predisposition or progression that may be more information than people 
want. For example, the known association of the gene ApoE with Alzheimer’s 
disease was identified during research on the polymorphisms of familial 
hyperlipoproteinemia (a form of cardiovascular disease).82 Procedures to 
gather the patient’s preferences for handling such collateral information—to 
tell or not to tell—will need to be developed and implemented.83 
race and pharmacogenomics — Many gene variants vary with geographic 
ancestry, including variants that are associated with drug response,84 and in-
deed physicians have long recognized that race can be an important variable 
in predicting how individuals will respond to certain medications. Researchers 
are now exploring the contribution of racial genetics to drug safety and efficacy. 
For example, researchers at the University of California at Los Angeles are 
looking for genetic factors that specifically influence how Mexican Americans, 
African Americans, and whites respond to several different antidepressants. 
FDA recently has required manufacturers of carbamazepine (used to treat 
epilepsy, bipolar disorder, and neuropathic pain) to warn on the label that 
patients of Asian ancestry are at risk for a rare but severe skin reaction from 
the drug and should have a genetic test before starting treatment. However, 
there are many social and scientific arguments both for and against the use 
of race and ethnicity to categorize subjects in pharmacogenomic research and 
practice. The FDA’s decision to approve the drug Bi-Dil for treatment of heart 
failure only in self-identified African Americans—the only subpopulation 
in which the clinical trial showed benefit—helped to crystallize the debate. 
Critics warned that drug research, development and approval based on the 
genetics of particular population groups could lead to new forms of social or 
medical stigmatization.85 They also pointed out that the correlation between 
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self-identified race and genetic ancestry is highly imperfect, particularly as 
multi-racial backgrounds become more common, and that a higher prevalence 
of a genetic variant in a racial or ethnic population does not predict whether 
any given individual member of that racial or ethnic group will have the 
variant. In addition, critics worry that distinctions based on race, rather than 
pathophysiology, might be trumped up for commercial advantage.86 Support-
ers of FDA’s decision argued that in the absence of more precise categories to 
identify responders versus non responders to the drug, self-identified race was 
the best available proxy to determine who will benefit (and who not) from a 
medication shown to be effective against a disease with high morbidity and 
mortality. Choosing to ignore the distinctions or waiting for different criteria 
to be developed would deny access to this useful drug to those who could 
benefit from it.87 Ultimately, pharmacogenomic research may provide its own 
key to this dilemma, by developing more accurate and specific descriptions 
of relevant genetic variations that could replace imprecise racial and/or ethnic 
categories in predicting drug response. 
concluSion
Many believe that pharmacogenomics offers enormous potential for improv-
ing drug safety and effectiveness as well as the productivity of the drug 
development pipeline. Indeed it is possible that some day each individual 
will carry his or her unique genetic profile on a chip that physicians will 
consult before prescribing. Today, however, only a small number of drugs 
are associated with a genetic test to determine whether that drug is appro-
priate for a given patient. 
Bringing pharmacogenomics from the realm of basic exploratory genet-
ics research to safe, effective applications in the doctor’s office will not 
be easy or inexpensive. It will require enormous investment and col-
laboration among a multitude of players, including the pharmaceutical, 
biotechnology, and diagnostics industries; their federal regulators; third-
party payers; health professionals and the institutions that train them; 
health information technology planners; and many others. The science 
is immensely challenging, and the cost of research needed to translate 
scientific findings into clinically useful tools is high. Significant issues 
arise from the current business models of the pharmaceutical, biotech-
nology, and diagnostics industries, overlaid with the need to update the 
regulatory framework to address potential safety issues while supporting 
the development of pharmacogenomic products. There are additional 
challenges that accompany the integration of any new technology into 
modern health care, including the need to prove value to the health care 
system, to manage uptake through appropriate coverage and reimburse-
ment policies and provider education, and to anticipate potentially sig-
nificant ethical and social implications. Few of these issues are unique to 
pharmacogenomics, but all will need to be explicitly considered in the 
context of this technology.
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